Cargando…
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
Background: The performance of immune checkpoint inhibitor (ICI) monotherapy was proved to be disappointing in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence has shown the promising efficacy of ICIs combined with systemic therapy in the first-line treatment in solid tumors. Case presen...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318868/ https://www.ncbi.nlm.nih.gov/pubmed/32636837 http://dx.doi.org/10.3389/fimmu.2020.01127 |
_version_ | 1783550945747009536 |
---|---|
author | Shui, Lin Cheng, Ke Li, Xiaofen Shui, Pixian Li, Shuangshuang Peng, Yang Li, Jian Guo, Fengzhu Yi, Cheng Cao, Dan |
author_facet | Shui, Lin Cheng, Ke Li, Xiaofen Shui, Pixian Li, Shuangshuang Peng, Yang Li, Jian Guo, Fengzhu Yi, Cheng Cao, Dan |
author_sort | Shui, Lin |
collection | PubMed |
description | Background: The performance of immune checkpoint inhibitor (ICI) monotherapy was proved to be disappointing in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence has shown the promising efficacy of ICIs combined with systemic therapy in the first-line treatment in solid tumors. Case presentation: We reported a case of a metastatic PDAC patient who had a long-term partial response and good tolerance to the combined approach of toripalimab (a novel PD-1 inhibitor) and gemcitabine plus nab-paclitaxel (GA). PD-L1 positive expression was detected in his liver metastases. Besides, we described a phenomenon of pseudo-progression of this patient during the course of therapy. Conclusion: As the first-line treatment of metastatic PDAC patients, GA plus toripalimab may provide a novel combined approach with favorable response and manageable toxicity. Further clinical trials are needed to confirm the results. Pseudo-progression requires special attention and to be differentiated with true progression in patients undergoing immunotherapy. |
format | Online Article Text |
id | pubmed-7318868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73188682020-07-06 Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Shui, Lin Cheng, Ke Li, Xiaofen Shui, Pixian Li, Shuangshuang Peng, Yang Li, Jian Guo, Fengzhu Yi, Cheng Cao, Dan Front Immunol Immunology Background: The performance of immune checkpoint inhibitor (ICI) monotherapy was proved to be disappointing in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence has shown the promising efficacy of ICIs combined with systemic therapy in the first-line treatment in solid tumors. Case presentation: We reported a case of a metastatic PDAC patient who had a long-term partial response and good tolerance to the combined approach of toripalimab (a novel PD-1 inhibitor) and gemcitabine plus nab-paclitaxel (GA). PD-L1 positive expression was detected in his liver metastases. Besides, we described a phenomenon of pseudo-progression of this patient during the course of therapy. Conclusion: As the first-line treatment of metastatic PDAC patients, GA plus toripalimab may provide a novel combined approach with favorable response and manageable toxicity. Further clinical trials are needed to confirm the results. Pseudo-progression requires special attention and to be differentiated with true progression in patients undergoing immunotherapy. Frontiers Media S.A. 2020-06-19 /pmc/articles/PMC7318868/ /pubmed/32636837 http://dx.doi.org/10.3389/fimmu.2020.01127 Text en Copyright © 2020 Shui, Cheng, Li, Shui, Li, Peng, Li, Guo, Yi and Cao. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Shui, Lin Cheng, Ke Li, Xiaofen Shui, Pixian Li, Shuangshuang Peng, Yang Li, Jian Guo, Fengzhu Yi, Cheng Cao, Dan Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma |
title | Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma |
title_full | Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma |
title_fullStr | Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma |
title_short | Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma |
title_sort | durable response and good tolerance to the triple combination of toripalimab, gemcitabine, and nab-paclitaxel in a patient with metastatic pancreatic ductal adenocarcinoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318868/ https://www.ncbi.nlm.nih.gov/pubmed/32636837 http://dx.doi.org/10.3389/fimmu.2020.01127 |
work_keys_str_mv | AT shuilin durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT chengke durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT lixiaofen durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT shuipixian durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT lishuangshuang durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT pengyang durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT lijian durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT guofengzhu durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT yicheng durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma AT caodan durableresponseandgoodtolerancetothetriplecombinationoftoripalimabgemcitabineandnabpaclitaxelinapatientwithmetastaticpancreaticductaladenocarcinoma |